Welcome to our dedicated page for Halozyme Thrp SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Halozyme’s royalty-rich disclosures can feel like searching for a single amino acid in a protein chain. The company’s 300-page reports weave ENHANZE licensing revenue, clinical trial spend, and complex milestone accounting into dense tables that few investors have time to unravel. If you have ever typed “Halozyme insider trading Form 4 transactions” or “Halozyme quarterly earnings report 10-Q filing” into a search bar, you already know the challenge.
Stock Titan solves the problem in minutes, not days. Our AI reads every 10-K, 10-Q, 8-K and S-3 the instant it hits EDGAR, then delivers plain-English answers to common questions such as “Halozyme SEC filings explained simply” and “understanding Halozyme SEC documents with AI.” Need to monitor material events? “Halozyme 8-K material events explained” appears with context minutes after filing. Want alerts on executive activity? “Halozyme Form 4 insider transactions real-time” and “Halozyme executive stock transactions Form 4” land in your dashboard before the market can react.
Each document is paired with concise AI summaries that spotlight: royalty percentages from Roche or Pfizer collaborations, pipeline milestone triggers, and cash-flow impacts of inventory builds. Use cases include:
- Comparing R&D burn across quarters with our “Halozyme earnings report filing analysis.”
- Reviewing compensation tables via “Halozyme proxy statement executive compensation.”
- Scanning the “Halozyme annual report 10-K simplified” section for segment revenue trends.
Whether you are modeling future royalties or timing trades around clinical catalysts, our real-time updates and expert insights transform raw HALO disclosures into decision-ready intelligence—no PhD in biochemistry required.
Halozyme Therapeutics (HALO) reported stronger quarterly results. For the three months ended September 30, 2025, total revenues were $354,264,000 versus $290,084,000 a year ago, driven by royalties of $236,038,000 and product sales of $94,228,000. Net income was $175,225,000 compared to $137,011,000, with diluted EPS of $1.43 versus $1.05.
For the nine months, revenue reached $944,844,000 versus $717,316,000, and net income was $458,480,000 versus $307,079,000, reflecting broad growth in royalties and milestones. Operating cash flow was $432,529,000, supporting cash and cash equivalents of $419,665,000 at quarter end.
The company repurchased common stock using $342,372,000 year-to-date. On the balance sheet, current portion of long-term debt, net, was $710,685,000 and long-term debt, net, was $800,072,000. Shares outstanding were 117,597,000 as of October 27, 2025. Stockholders’ equity increased to $503,915,000 from $363,821,000 at December 31, 2024.
Halozyme Therapeutics, Inc. furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The release was provided as Exhibit 99.1 under Item 2.02.
The company also disclosed a planned CFO transition. Nicole LaBrosse, Senior Vice President and Chief Financial Officer, will continue as CFO until the earlier of when a new CFO is hired or March 30, 2026, after which she will depart to pursue a new professional opportunity. Halozyme has initiated a search for its next CFO.
The company stated that Ms. LaBrosse’s departure is not due to any disagreement with its independent auditors or with the company regarding financial statements, internal control over financial reporting, operations, policies, or practices. The company expects to enter into a transition and release agreement with Ms. LaBrosse.
Halozyme Therapeutics (HALO) furnished a Regulation FD update announcing it issued a statement on the final IPAY 2028 guidance for Medicare price negotiations from the U.S. Centers for Medicare & Medicaid Services. The statement includes the company’s long‑term projections of U.S. Medicare Part B spend as a percentage of total ENHANZE partner product subcutaneous sales. The statement is available on the company’s website and attached as Exhibit 99.1. This information is furnished under Item 7.01 and is not deemed filed or incorporated by reference.
Officer equity grants and option exercise reported. The reporting person, Cortney Caudill, SVP and Chief Operating Officer, acquired 9,031 shares via an option exercise with an exercise price of
HALO officer Cortney Caudill filed an initial Form 3 reporting direct ownership of 7,674 shares and equity awards that can convert to common stock. The reported awards include stock options exercisable for 89,224 and 11,302 shares with exercise prices of
Halozyme Therapeutics entered into an Agreement and Plan of Merger to combine with Elektrofi, Inc. under which Halozyme's wholly owned subsidiary Erraid Merger Sub Inc. will merge into Elektrofi and Elektrofi will survive as a wholly owned subsidiary of Halozyme. The filing names Shareholder Representative Services LLC as the securityholders' representative. The disclosure describes the planned corporate combination but does not disclose financial terms, timing, or regulatory approvals in the provided excerpt.
Halozyme Therapeutics (HALO) Form 144 notice reports a proposed sale of 136,569 shares of common stock through J.P. Morgan Securities, with an aggregate market value reported as $10,015,970 and an approximate sale date of 10/01/2025 on NASDAQ. The filing shows the shares were acquired on 10/01/2025 via stock option exercise and paid in cash. Recent disclosed sales by the same person, Helen Torley, list nine separate transactions from 07/08/2025 through 09/04/2025, each of 20,000 shares, with gross proceeds shown for each trade.
Nicole LaBrosse, SVP and Chief Financial Officer of Halozyme Therapeutics (HALO), reported two open-market sales of common stock on 09/22/2025 executed under a Rule 10b5-1 trading plan adopted on June 11, 2025. The Form 4 shows a sale of 1,913 shares at a weighted-average price of $77.827 (prices in the range $77.34–$78.32) and a sale of 314 shares at a weighted-average price of $78.667 (range $78.37–$79.18).
Following the reported transactions, the beneficial ownership reported was 22,079 shares (direct). The filing was signed on behalf of the reporting person by an attorney-in-fact on 09/23/2025. The Form 4 discloses that the sales were effected by a broker pursuant to the 10b5-1 plan and provides weighted-average price ranges with an offer to furnish per-price quantities on request.
FAQ
What is the current stock price of Halozyme Thrp (HALO)?
What is the market cap of Halozyme Thrp (HALO)?
